Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NMUS_IS_HEADED_WAY_UP!!!$1+__SOON_IN_MY_OPINION!!!
WE HAVE EXCLUSIVE ACCESS TO 49 YEARS WORTH OF CANNABIS FEDERAL RESEARCH ! NOT EVEN OUR COMPETITORS $GWPH, $ZYNE, $INSY, OR $CARA 's HAVE THIS TYPE OF RESEARCH AT THEIR DISPOSAL! BTW $ETST RECENTLY EXPLODED IN THE PAST COUPLE OF DAYS. THEY ARE A DIRECT COMPETITOR AND HAVE A MARKET CAP AT ALMOST 7X $NMUS AND THEY DONT EVEN HAVE THIS TYPE OF INTELLECTUAL PROPERTY!
WE OWN THE EXCLUSIVE RIGHTS!!
PER THE RECENT CEO INTERVIEW:
NMUS is growing and is charting a course for growth in the near term. From managements perspective, they are already well on their way.
Q. In looking at NEMUS' portfolio of cannabinoid product candidates and the unique relationship with The University of Mississippi, can you provide us with an overview of the pipeline and patent portfolio?
The University of Mississippi has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968. By virtue of the University's 49-year experience with the Cannabis plant, Nemus benefits tremendously from the University's knowledge. Nemus is the sole developmental and commercialization partner with the University and has exclusive, global licenses to intellectual property related to these molecules.
$NMUS Under Accumulation: SEE_CHART__BREAKOUT_IN_PROGRESS! 5 Million Shares on the Public Freely Tradeable Float!
1st Time Above Trend Line since the Last Run that took it to almost $2 in a Few Days!
Nemus Bioscience (NMUS) OTHER OTC
0.4200 +0.0010 +0.24%
02/03/17
TECHNICAL CHART
for Fri, Feb 3rd, 2017
https://www.barchart.com/stocks/quotes/NMUS/technical-chart#/technical-chart?plot=BAR&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=SMA(50);SMA(10);SMA(5)&sym=NMUS&grid=1&height=500&studyheight=100
$NMUS Under Accumulation: SEE_CHART__BREAKOUT_IN_PROGRESS! 5 Million Shares on the Public Freely Tradeable Float!
1st Time Above Trend Line since the Last Run that took it to almost $2 in a Few Days!
Nemus Bioscience (NMUS) OTHER OTC
0.4200 +0.0010 +0.24%
02/03/17
TECHNICAL CHART
for Fri, Feb 3rd, 2017
https://www.barchart.com/stocks/quotes/NMUS/technical-chart#/technical-chart?plot=BAR&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=SMA(50);SMA(10);SMA(5)&sym=NMUS&grid=1&height=500&studyheight=100
$NMUS_IS_HEADED_WAY_UP!!!$1+__SOON_IN_MY_OPINION!!!
WE HAVE EXCLUSIVE ACCESS TO 49 YEARS WORTH OF CANNABIS FEDERAL RESEARCH !
NOT EVEN OUR COMPETITORS $GWPH, $ZYNE, $INSY, OR $CARA 's HAVE THIS TYPE OF RESEARCH AT THEIR DISPOSAL! BTW $ETST RECENTLY EXPLODED IN THE PAST COUPLE OF DAYS. THEY ARE A DIRECT COMPETITOR AND HAVE A MARKET CAP AT ALMOST 7X $NMUS AND THEY DON'T EVEN HAVE THIS TYPE OF INTELLECTUAL PROPERTY!
WE OWN THE EXCLUSIVE RIGHTS!!
PER THE RECENT CEO INTERVIEW:
NMUS is growing and is charting a course for growth in the near term. From managements perspective, they are already well on their way.
Q. In looking at NEMUS' portfolio of cannabinoid product candidates and the unique relationship with The University of Mississippi, can you provide us with an overview of the pipeline and patent portfolio?
The University of Mississippi has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968. By virtue of the University's 49-year experience with the Cannabis plant, Nemus benefits tremendously from the University's knowledge. Nemus is the sole developmental and commercialization partner with the University and has exclusive, global licenses to intellectual property related to these molecules.
$NMUS_IS_HEADED_WAY_UP!!!$1+__SOON_IN_MY_OPINION!!!
WE HAVE EXCLUSIVE ACCESS TO 49 YEARS WORTH OF CANNABIS FEDERAL RESEARCH !
NOT EVEN OUR COMPETITORS $GWPH, $ZYNE, $INSY, OR $CARA 's HAVE THIS TYPE OF RESEARCH AT THEIR DISPOSAL! BTW $ETST RECENTLY EXPLODED IN THE PAST COUPLE OF DAYS. THEY ARE A DIRECT COMPETITOR AND HAVE A MARKET CAP AT ALMOST 7X $NMUS AND THEY DON'T EVEN HAVE THIS TYPE OF INTELLECTUAL PROPERTY!
WE OWN THE EXCLUSIVE RIGHTS!!
PER THE RECENT CEO INTERVIEW:
NMUS is growing and is charting a course for growth in the near term. From managements perspective, they are already well on their way.
Q. In looking at NEMUS' portfolio of cannabinoid product candidates and the unique relationship with The University of Mississippi, can you provide us with an overview of the pipeline and patent portfolio?
The University of Mississippi has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968. By virtue of the University's 49-year experience with the Cannabis plant, Nemus benefits tremendously from the University's knowledge. Nemus is the sole developmental and commercialization partner with the University and has exclusive, global licenses to intellectual property related to these molecules.
$NMUS FULL CEO Interview A Sit Down With Nemus Bioscience; Cannabinoids In Focus - Nemus Bioscience, Inc. (OTCMKTS:NMUS) | Seeking Alpha
A Sit Down With Nemus Bioscience; Cannabinoids In Focus
Feb. 1, 2017 11:06 AM ET Nemus Bioscience, Inc. (NMUS)
Summary
Cannabinoids are fast becoming an interesting market with proven efficacy for a host of disease and illness.
Separating cannabinoid companies from marijuana stocks is a critically important aspect of investing in the sector.
NMUS is well connected with educational institutions, has some strong license agreements and may capitalize from increased interest in cannabinoid based therapy.
I have received enough questions from followers about Nemus Bioscience (OTCQB:NMUS) that my curiosity was finally piqued to the point of action. While Seeking Alpha has certainly presented a fair share of information and analysis about NMUS, the time is probably ripe for management to provide a detailed update as to the current state of NMUS, as well as to provide guidance on its near term ambitions.
Being that as it may, I went straight to the source, and NMUS management was more than receptive to providing some current data and to provide investors with a fresh take on what NMUS is working to accomplish.
From my point of view, NMUS is growing and is charting a course for growth in the near term. From managements perspective, they are already well on their way.
Q. In looking at NEMUS' portfolio of cannabinoid product candidates and the unique relationship with The University of Mississippi, can you provide us with an overview of the pipeline and patent portfolio?
The University of Mississippi has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968. By virtue of the University's 49-year experience with the Cannabis plant, Nemus benefits tremendously from the University's knowledge. Nemus is the sole developmental and commercialization partner with the University and has exclusive, global licenses to intellectual property related to these molecules.
Those licenses include access to intellectual property for both a prodrug of tetrahydrocannabinol (THC) and an analogue of cannabidiol (CBD). The THC-prodrug is being developed as a therapeutic agent for glaucoma and chemotherapy-induced nausea and vomiting (CINV). The analogue of CBD is being explored as a possible therapeutic for chemotherapy-induced peripheral neuropathy (CIPN) and other pain syndromes. Lastly, Nemus is developing cannabinoid-based platforms for use as anti-infectives, especially for use against bacteria and viruses that have developed resistance to established therapies.
Q. Often times investors confuse pharmaceutical-based cannabinoids with plant derived products. Can you give a layman's overview of the difference and significance from a regulatory standpoint?
The Cannabis plant is known to have more than 100 different cannabinoid molecules. These molecules can possess diverse activity at the cellular level in multiple organs in the body. Plant-derived molecules are very hydrophobic or not that soluble in water. The lack of significant water solubility makes these molecules difficult to administer into the body, especially by oral ingestion. Nemus' cannabinoid molecules have been re-engineered to make them chemically more hydrophilic or water soluble, so they can traverse cellular membranes easier with the goal that they can be absorbed in a more predictable and safer way. Patents have been issued for compounds licensed by Nemus that have intellectual property claims related to composition of matter, methods of synthesis, and methods of use.
Nemus cannabinoid molecules are being chemically synthesized to meet purity and scale-up criteria for eventual commercialization. The synthetic manufacturing process must meet DEA and FDA specifications for cannabinoid-based drug product. Furthermore, Nemus plans to conduct the necessary pre-clinical and clinical studies so these molecules meet the specifications to be an approvable drug product.
Q. In terms of competition in the space with GW Pharma, Zynerba, and Insys, how do you feel NEMUS should be compared?
Nemus is an early-stage developmental company compared to the listed cannabinoid-market incumbents. We aspire to be a second-generation market disruptor.
a) Nemus does not rely on plant extraction for its drug product candidates and in fact, by virtue of biosynthetic manufacturing, can potentially develop high-purity active pharmaceutical ingredients (APIs) with associated shorter manufacturing times.
b) Nemus's portfolio consists of re-engineered cannabinoids, a prodrug of THC and an analogue of CBD. These drug product candidates are designed to have multiple routes of administration specific to the disease indication that could potentially give Nemus a competitive advantage on issues of bio-distribution, bioavailability, and pharmacokinetics.
c) Unlike companies that use traditional plant cannabinoids, Nemus' licensed bio-engineered molecules have been issued patents for composition of matter as well as methods of use. Consequently, Nemus may not have to rely on orphan indications for market exclusivity but could approach entire therapeutic areas globally. These markets, namely glaucoma, pain, methicillin-resistant Staphylococcus aureus (MRSA) and CINV, are all multi-billion dollar global opportunities with an urgent medical need for newer, safe and effective therapies.
d) Nemus currently holds some market distinctions, including, to our knowledge, being the only cannabinoid company developing a portfolio of drug candidates for use in ophthalmology, with a leading indication being glaucoma; the only cannabinoid company developing an anti-infective platform against multiple infectious agents; the only cannabinoid company utilizing biosynthetic manufacturing; and the only cannabinoid company with prodrug and analogue capability with multiple potential routes of administration including ocular, trans-mucosal/buccal, transdermal, and transmembranous delivery that avoids first-pass metabolism by the liver.
Q. With GW Pharma being the most advanced in the clinic with a market cap of almost $3 Billion, how do you see NEMUS moving forward with GW having the first mover advantage?
With a pipeline bio-engineered with the goal of better target-organ access, we believe Nemus can be a classical second-mover to capitalize on unmet medical needs of first-in-class drugs. Those needs include: more rapid onset of action, predictable bioavailability and pharmacokinetics, routes of administration that avoid first-pass liver metabolism, versatility in dosing mechanisms, and efficient API manufacturing. We believe Nemus will be able to enter large therapeutic areas versus having to focus on orphan indications.
Q. From a regulatory standpoint at the federal level and some of the laws that have been passed, do you believe the current administration will loosen plant-based cannabinoids versus pharmaceutical, and how would that impact your business model?
Time will tell what the new administration's position will be. For pharmaceutical developers, the pathway to drug approval is carefully delineated and all drugs must meet the criteria set by the regulatory agencies. If marijuana is re-scheduled as a Schedule II drug, pharmaceutical developers will be required to conduct clinical trials and have scientifically rigorous data to make claims about and promote the medicinal benefits of the Cannibas plant as was done with other Schedule II medications like oxycontin. Nemus plans to conduct research and development in accordance with FDA standards so the proper regulatory filings can be made to reach drug approval.
Q. Looking forward at how you advance your portfolio, should investors be looking at structures such as co-development or licensing agreements, and are there examples of such in the cannabinoid industry?
It will come as no surprise to anyone that drug development is time consuming and expensive, especially on a global scale. Nemus has access to patents and compounds that have shown activity in both in vitro and animal testing. To maximize shareholder value, Nemus is open to explore strategic collaborations with partners that can help expedite our goals to commercialize our pipeline. That collaboration could possibly take the form of a co-development deal, an in-licensing of our products, or an outright acquisition of a promising platform, especially one that requires resources that an early-stage biotechnology company may not have.
Mature companies in the cannabinoid sector like GW Pharma have also partnered with larger firms, especially those that can provide development capital and provide sales capabilities in overseas territories. We anticipate that this will be more the rule than the exception as breakthrough companies in the pharmaceuticalized cannabinoid space expand their capabilities.
Q. In closing, given all of the developments that have occurred both in NEMUS and the cannabinoid sector over the past year, what should investors focus on in 2017?
I believe investors will see strides in the cannabinoid sector beyond pain and epilepsy as companies like Nemus advance other cannabinoid molecules for newer indications. I feel the cannabinoid sector is a hyper-competitive space and there will be greater emphasis to expand treatment options utilizing different routes of administration to enhance safety and the clinical response. Nemus has licenses from the University of Mississippi that allow the company to develop unique methods to administer our novel forms of cannabinoids and we look forward to introducing these approaches into the development pipeline in 2017.
End interview
While technically not a marijuana stock, NMUS will most likely rise and fall with the sector, at least until the market fully understands the differentiating features of the company. NMUS is certainly a stock to keep an eye on in the near term, as cannabinoids are becoming increasingly popular in clinical trials and are demonstrating significant therapeutic benefit for a host of disease and illness.
Thanks to Brian Murphy and the rest of the management team at NMUS for taking the time to update shareholders. While all small caps have risk, the ones that have a clear plan of action hold the most promise of making it out of penny land alive. For NMUS, as long as management can stay focused to their tasks at hand and remain steadfast to their corporate responsibilities, they may fare well in the next 12-24 months.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
http://seekingalpha.com/article/4041487-sit-nemus-bioscience-cannabinoids-focus
$NMUS FLOAT_REMAINS_UNCHANGED_AT_5,005,713
Market Value1 $9,401,590 a/o Feb 02, 2017
Authorized Shares 236,000,000 a/o Feb 01, 2017
Outstanding Shares 22,438,163 a/o Feb 01, 2017
-Restricted 13,494,621 a/o Feb 01, 2017
-Unrestricted 8,943,542 a/o Feb 01, 2017
Held at DTC Not Available
Float 5,005,713 a/o Mar 23, 2016
$NMUS FLOAT_REMAINS_UNCHANGED_AT_5,005,713
Market Value1 $9,401,590 a/o Feb 02, 2017
Authorized Shares 236,000,000 a/o Feb 01, 2017
Outstanding Shares 22,438,163 a/o Feb 01, 2017
-Restricted 13,494,621 a/o Feb 01, 2017
-Unrestricted 8,943,542 a/o Feb 01, 2017
Held at DTC Not Available
Float 5,005,713 a/o Mar 23, 2016
$NMUS FULL CEO Interview A Sit Down With Nemus Bioscience; Cannabinoids In Focus - Nemus Bioscience, Inc. (OTCMKTS:NMUS) | Seeking Alpha
A Sit Down With Nemus Bioscience; Cannabinoids In Focus
Feb. 1, 2017 11:06 AM ET Nemus Bioscience, Inc. (NMUS)
Summary
Cannabinoids are fast becoming an interesting market with proven efficacy for a host of disease and illness.
Separating cannabinoid companies from marijuana stocks is a critically important aspect of investing in the sector.
NMUS is well connected with educational institutions, has some strong license agreements and may capitalize from increased interest in cannabinoid based therapy.
I have received enough questions from followers about Nemus Bioscience (OTCQB:NMUS) that my curiosity was finally piqued to the point of action. While Seeking Alpha has certainly presented a fair share of information and analysis about NMUS, the time is probably ripe for management to provide a detailed update as to the current state of NMUS, as well as to provide guidance on its near term ambitions.
Being that as it may, I went straight to the source, and NMUS management was more than receptive to providing some current data and to provide investors with a fresh take on what NMUS is working to accomplish.
From my point of view, NMUS is growing and is charting a course for growth in the near term. From managements perspective, they are already well on their way.
Q. In looking at NEMUS' portfolio of cannabinoid product candidates and the unique relationship with The University of Mississippi, can you provide us with an overview of the pipeline and patent portfolio?
The University of Mississippi has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968. By virtue of the University's 49-year experience with the Cannabis plant, Nemus benefits tremendously from the University's knowledge. Nemus is the sole developmental and commercialization partner with the University and has exclusive, global licenses to intellectual property related to these molecules.
Those licenses include access to intellectual property for both a prodrug of tetrahydrocannabinol (THC) and an analogue of cannabidiol (CBD). The THC-prodrug is being developed as a therapeutic agent for glaucoma and chemotherapy-induced nausea and vomiting (CINV). The analogue of CBD is being explored as a possible therapeutic for chemotherapy-induced peripheral neuropathy (CIPN) and other pain syndromes. Lastly, Nemus is developing cannabinoid-based platforms for use as anti-infectives, especially for use against bacteria and viruses that have developed resistance to established therapies.
Q. Often times investors confuse pharmaceutical-based cannabinoids with plant derived products. Can you give a layman's overview of the difference and significance from a regulatory standpoint?
The Cannabis plant is known to have more than 100 different cannabinoid molecules. These molecules can possess diverse activity at the cellular level in multiple organs in the body. Plant-derived molecules are very hydrophobic or not that soluble in water. The lack of significant water solubility makes these molecules difficult to administer into the body, especially by oral ingestion. Nemus' cannabinoid molecules have been re-engineered to make them chemically more hydrophilic or water soluble, so they can traverse cellular membranes easier with the goal that they can be absorbed in a more predictable and safer way. Patents have been issued for compounds licensed by Nemus that have intellectual property claims related to composition of matter, methods of synthesis, and methods of use.
Nemus cannabinoid molecules are being chemically synthesized to meet purity and scale-up criteria for eventual commercialization. The synthetic manufacturing process must meet DEA and FDA specifications for cannabinoid-based drug product. Furthermore, Nemus plans to conduct the necessary pre-clinical and clinical studies so these molecules meet the specifications to be an approvable drug product.
Q. In terms of competition in the space with GW Pharma, Zynerba, and Insys, how do you feel NEMUS should be compared?
Nemus is an early-stage developmental company compared to the listed cannabinoid-market incumbents. We aspire to be a second-generation market disruptor.
a) Nemus does not rely on plant extraction for its drug product candidates and in fact, by virtue of biosynthetic manufacturing, can potentially develop high-purity active pharmaceutical ingredients (APIs) with associated shorter manufacturing times.
b) Nemus's portfolio consists of re-engineered cannabinoids, a prodrug of THC and an analogue of CBD. These drug product candidates are designed to have multiple routes of administration specific to the disease indication that could potentially give Nemus a competitive advantage on issues of bio-distribution, bioavailability, and pharmacokinetics.
c) Unlike companies that use traditional plant cannabinoids, Nemus' licensed bio-engineered molecules have been issued patents for composition of matter as well as methods of use. Consequently, Nemus may not have to rely on orphan indications for market exclusivity but could approach entire therapeutic areas globally. These markets, namely glaucoma, pain, methicillin-resistant Staphylococcus aureus (MRSA) and CINV, are all multi-billion dollar global opportunities with an urgent medical need for newer, safe and effective therapies.
d) Nemus currently holds some market distinctions, including, to our knowledge, being the only cannabinoid company developing a portfolio of drug candidates for use in ophthalmology, with a leading indication being glaucoma; the only cannabinoid company developing an anti-infective platform against multiple infectious agents; the only cannabinoid company utilizing biosynthetic manufacturing; and the only cannabinoid company with prodrug and analogue capability with multiple potential routes of administration including ocular, trans-mucosal/buccal, transdermal, and transmembranous delivery that avoids first-pass metabolism by the liver.
Q. With GW Pharma being the most advanced in the clinic with a market cap of almost $3 Billion, how do you see NEMUS moving forward with GW having the first mover advantage?
With a pipeline bio-engineered with the goal of better target-organ access, we believe Nemus can be a classical second-mover to capitalize on unmet medical needs of first-in-class drugs. Those needs include: more rapid onset of action, predictable bioavailability and pharmacokinetics, routes of administration that avoid first-pass liver metabolism, versatility in dosing mechanisms, and efficient API manufacturing. We believe Nemus will be able to enter large therapeutic areas versus having to focus on orphan indications.
Q. From a regulatory standpoint at the federal level and some of the laws that have been passed, do you believe the current administration will loosen plant-based cannabinoids versus pharmaceutical, and how would that impact your business model?
Time will tell what the new administration's position will be. For pharmaceutical developers, the pathway to drug approval is carefully delineated and all drugs must meet the criteria set by the regulatory agencies. If marijuana is re-scheduled as a Schedule II drug, pharmaceutical developers will be required to conduct clinical trials and have scientifically rigorous data to make claims about and promote the medicinal benefits of the Cannibas plant as was done with other Schedule II medications like oxycontin. Nemus plans to conduct research and development in accordance with FDA standards so the proper regulatory filings can be made to reach drug approval.
Q. Looking forward at how you advance your portfolio, should investors be looking at structures such as co-development or licensing agreements, and are there examples of such in the cannabinoid industry?
It will come as no surprise to anyone that drug development is time consuming and expensive, especially on a global scale. Nemus has access to patents and compounds that have shown activity in both in vitro and animal testing. To maximize shareholder value, Nemus is open to explore strategic collaborations with partners that can help expedite our goals to commercialize our pipeline. That collaboration could possibly take the form of a co-development deal, an in-licensing of our products, or an outright acquisition of a promising platform, especially one that requires resources that an early-stage biotechnology company may not have.
Mature companies in the cannabinoid sector like GW Pharma have also partnered with larger firms, especially those that can provide development capital and provide sales capabilities in overseas territories. We anticipate that this will be more the rule than the exception as breakthrough companies in the pharmaceuticalized cannabinoid space expand their capabilities.
Q. In closing, given all of the developments that have occurred both in NEMUS and the cannabinoid sector over the past year, what should investors focus on in 2017?
I believe investors will see strides in the cannabinoid sector beyond pain and epilepsy as companies like Nemus advance other cannabinoid molecules for newer indications. I feel the cannabinoid sector is a hyper-competitive space and there will be greater emphasis to expand treatment options utilizing different routes of administration to enhance safety and the clinical response. Nemus has licenses from the University of Mississippi that allow the company to develop unique methods to administer our novel forms of cannabinoids and we look forward to introducing these approaches into the development pipeline in 2017.
End interview
While technically not a marijuana stock, NMUS will most likely rise and fall with the sector, at least until the market fully understands the differentiating features of the company. NMUS is certainly a stock to keep an eye on in the near term, as cannabinoids are becoming increasingly popular in clinical trials and are demonstrating significant therapeutic benefit for a host of disease and illness.
Thanks to Brian Murphy and the rest of the management team at NMUS for taking the time to update shareholders. While all small caps have risk, the ones that have a clear plan of action hold the most promise of making it out of penny land alive. For NMUS, as long as management can stay focused to their tasks at hand and remain steadfast to their corporate responsibilities, they may fare well in the next 12-24 months.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
http://seekingalpha.com/article/4041487-sit-nemus-bioscience-cannabinoids-focus
End of the Quarter is March, Right!
Huge News Coming for $NMUS, Hope You guys Realize How Big this will be!
$NMUS 5 Million Share Float CANNABINOID PLAY Like $ZYNE $CARA $GWPH $INSY
$NMUS FULL CEO Interview A Sit Down With Nemus Bioscience; Cannabinoids In Focus - Nemus Bioscience, Inc. (OTCMKTS:NMUS) | Seeking Alpha
A Sit Down With Nemus Bioscience; Cannabinoids In Focus
Feb. 1, 2017 11:06 AM ET Nemus Bioscience, Inc. (NMUS)
Summary
Cannabinoids are fast becoming an interesting market with proven efficacy for a host of disease and illness.
Separating cannabinoid companies from marijuana stocks is a critically important aspect of investing in the sector.
NMUS is well connected with educational institutions, has some strong license agreements and may capitalize from increased interest in cannabinoid based therapy.
I have received enough questions from followers about Nemus Bioscience (OTCQB:NMUS) that my curiosity was finally piqued to the point of action. While Seeking Alpha has certainly presented a fair share of information and analysis about NMUS, the time is probably ripe for management to provide a detailed update as to the current state of NMUS, as well as to provide guidance on its near term ambitions.
Being that as it may, I went straight to the source, and NMUS management was more than receptive to providing some current data and to provide investors with a fresh take on what NMUS is working to accomplish.
From my point of view, NMUS is growing and is charting a course for growth in the near term. From managements perspective, they are already well on their way.
Q. In looking at NEMUS' portfolio of cannabinoid product candidates and the unique relationship with The University of Mississippi, can you provide us with an overview of the pipeline and patent portfolio?
The University of Mississippi has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968. By virtue of the University's 49-year experience with the Cannabis plant, Nemus benefits tremendously from the University's knowledge. Nemus is the sole developmental and commercialization partner with the University and has exclusive, global licenses to intellectual property related to these molecules.
Those licenses include access to intellectual property for both a prodrug of tetrahydrocannabinol (THC) and an analogue of cannabidiol (CBD). The THC-prodrug is being developed as a therapeutic agent for glaucoma and chemotherapy-induced nausea and vomiting (CINV). The analogue of CBD is being explored as a possible therapeutic for chemotherapy-induced peripheral neuropathy (CIPN) and other pain syndromes. Lastly, Nemus is developing cannabinoid-based platforms for use as anti-infectives, especially for use against bacteria and viruses that have developed resistance to established therapies.
Q. Often times investors confuse pharmaceutical-based cannabinoids with plant derived products. Can you give a layman's overview of the difference and significance from a regulatory standpoint?
The Cannabis plant is known to have more than 100 different cannabinoid molecules. These molecules can possess diverse activity at the cellular level in multiple organs in the body. Plant-derived molecules are very hydrophobic or not that soluble in water. The lack of significant water solubility makes these molecules difficult to administer into the body, especially by oral ingestion. Nemus' cannabinoid molecules have been re-engineered to make them chemically more hydrophilic or water soluble, so they can traverse cellular membranes easier with the goal that they can be absorbed in a more predictable and safer way. Patents have been issued for compounds licensed by Nemus that have intellectual property claims related to composition of matter, methods of synthesis, and methods of use.
Nemus cannabinoid molecules are being chemically synthesized to meet purity and scale-up criteria for eventual commercialization. The synthetic manufacturing process must meet DEA and FDA specifications for cannabinoid-based drug product. Furthermore, Nemus plans to conduct the necessary pre-clinical and clinical studies so these molecules meet the specifications to be an approvable drug product.
Q. In terms of competition in the space with GW Pharma, Zynerba, and Insys, how do you feel NEMUS should be compared?
Nemus is an early-stage developmental company compared to the listed cannabinoid-market incumbents. We aspire to be a second-generation market disruptor.
a) Nemus does not rely on plant extraction for its drug product candidates and in fact, by virtue of biosynthetic manufacturing, can potentially develop high-purity active pharmaceutical ingredients (APIs) with associated shorter manufacturing times.
b) Nemus's portfolio consists of re-engineered cannabinoids, a prodrug of THC and an analogue of CBD. These drug product candidates are designed to have multiple routes of administration specific to the disease indication that could potentially give Nemus a competitive advantage on issues of bio-distribution, bioavailability, and pharmacokinetics.
c) Unlike companies that use traditional plant cannabinoids, Nemus' licensed bio-engineered molecules have been issued patents for composition of matter as well as methods of use. Consequently, Nemus may not have to rely on orphan indications for market exclusivity but could approach entire therapeutic areas globally. These markets, namely glaucoma, pain, methicillin-resistant Staphylococcus aureus (MRSA) and CINV, are all multi-billion dollar global opportunities with an urgent medical need for newer, safe and effective therapies.
d) Nemus currently holds some market distinctions, including, to our knowledge, being the only cannabinoid company developing a portfolio of drug candidates for use in ophthalmology, with a leading indication being glaucoma; the only cannabinoid company developing an anti-infective platform against multiple infectious agents; the only cannabinoid company utilizing biosynthetic manufacturing; and the only cannabinoid company with prodrug and analogue capability with multiple potential routes of administration including ocular, trans-mucosal/buccal, transdermal, and transmembranous delivery that avoids first-pass metabolism by the liver.
Q. With GW Pharma being the most advanced in the clinic with a market cap of almost $3 Billion, how do you see NEMUS moving forward with GW having the first mover advantage?
With a pipeline bio-engineered with the goal of better target-organ access, we believe Nemus can be a classical second-mover to capitalize on unmet medical needs of first-in-class drugs. Those needs include: more rapid onset of action, predictable bioavailability and pharmacokinetics, routes of administration that avoid first-pass liver metabolism, versatility in dosing mechanisms, and efficient API manufacturing. We believe Nemus will be able to enter large therapeutic areas versus having to focus on orphan indications.
Q. From a regulatory standpoint at the federal level and some of the laws that have been passed, do you believe the current administration will loosen plant-based cannabinoids versus pharmaceutical, and how would that impact your business model?
Time will tell what the new administration's position will be. For pharmaceutical developers, the pathway to drug approval is carefully delineated and all drugs must meet the criteria set by the regulatory agencies. If marijuana is re-scheduled as a Schedule II drug, pharmaceutical developers will be required to conduct clinical trials and have scientifically rigorous data to make claims about and promote the medicinal benefits of the Cannibas plant as was done with other Schedule II medications like oxycontin. Nemus plans to conduct research and development in accordance with FDA standards so the proper regulatory filings can be made to reach drug approval.
Q. Looking forward at how you advance your portfolio, should investors be looking at structures such as co-development or licensing agreements, and are there examples of such in the cannabinoid industry?
It will come as no surprise to anyone that drug development is time consuming and expensive, especially on a global scale. Nemus has access to patents and compounds that have shown activity in both in vitro and animal testing. To maximize shareholder value, Nemus is open to explore strategic collaborations with partners that can help expedite our goals to commercialize our pipeline. That collaboration could possibly take the form of a co-development deal, an in-licensing of our products, or an outright acquisition of a promising platform, especially one that requires resources that an early-stage biotechnology company may not have.
Mature companies in the cannabinoid sector like GW Pharma have also partnered with larger firms, especially those that can provide development capital and provide sales capabilities in overseas territories. We anticipate that this will be more the rule than the exception as breakthrough companies in the pharmaceuticalized cannabinoid space expand their capabilities.
Q. In closing, given all of the developments that have occurred both in NEMUS and the cannabinoid sector over the past year, what should investors focus on in 2017?
I believe investors will see strides in the cannabinoid sector beyond pain and epilepsy as companies like Nemus advance other cannabinoid molecules for newer indications. I feel the cannabinoid sector is a hyper-competitive space and there will be greater emphasis to expand treatment options utilizing different routes of administration to enhance safety and the clinical response. Nemus has licenses from the University of Mississippi that allow the company to develop unique methods to administer our novel forms of cannabinoids and we look forward to introducing these approaches into the development pipeline in 2017.
End interview
While technically not a marijuana stock, NMUS will most likely rise and fall with the sector, at least until the market fully understands the differentiating features of the company. NMUS is certainly a stock to keep an eye on in the near term, as cannabinoids are becoming increasingly popular in clinical trials and are demonstrating significant therapeutic benefit for a host of disease and illness.
Thanks to Brian Murphy and the rest of the management team at NMUS for taking the time to update shareholders. While all small caps have risk, the ones that have a clear plan of action hold the most promise of making it out of penny land alive. For NMUS, as long as management can stay focused to their tasks at hand and remain steadfast to their corporate responsibilities, they may fare well in the next 12-24 months.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
http://seekingalpha.com/article/4041487-sit-nemus-bioscience-cannabinoids-focus
$NMUS FULL CEO Interview A Sit Down With Nemus Bioscience; Cannabinoids In Focus - Nemus Bioscience, Inc. (OTCMKTS:NMUS) | Seeking Alpha
A Sit Down With Nemus Bioscience; Cannabinoids In Focus
Feb. 1, 2017 11:06 AM ET Nemus Bioscience, Inc. (NMUS)
Summary
Cannabinoids are fast becoming an interesting market with proven efficacy for a host of disease and illness.
Separating cannabinoid companies from marijuana stocks is a critically important aspect of investing in the sector.
NMUS is well connected with educational institutions, has some strong license agreements and may capitalize from increased interest in cannabinoid based therapy.
I have received enough questions from followers about Nemus Bioscience (OTCQB:NMUS) that my curiosity was finally piqued to the point of action. While Seeking Alpha has certainly presented a fair share of information and analysis about NMUS, the time is probably ripe for management to provide a detailed update as to the current state of NMUS, as well as to provide guidance on its near term ambitions.
Being that as it may, I went straight to the source, and NMUS management was more than receptive to providing some current data and to provide investors with a fresh take on what NMUS is working to accomplish.
From my point of view, NMUS is growing and is charting a course for growth in the near term. From managements perspective, they are already well on their way.
Q. In looking at NEMUS' portfolio of cannabinoid product candidates and the unique relationship with The University of Mississippi, can you provide us with an overview of the pipeline and patent portfolio?
The University of Mississippi has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968. By virtue of the University's 49-year experience with the Cannabis plant, Nemus benefits tremendously from the University's knowledge. Nemus is the sole developmental and commercialization partner with the University and has exclusive, global licenses to intellectual property related to these molecules.
Those licenses include access to intellectual property for both a prodrug of tetrahydrocannabinol (THC) and an analogue of cannabidiol (CBD). The THC-prodrug is being developed as a therapeutic agent for glaucoma and chemotherapy-induced nausea and vomiting (CINV). The analogue of CBD is being explored as a possible therapeutic for chemotherapy-induced peripheral neuropathy (CIPN) and other pain syndromes. Lastly, Nemus is developing cannabinoid-based platforms for use as anti-infectives, especially for use against bacteria and viruses that have developed resistance to established therapies.
Q. Often times investors confuse pharmaceutical-based cannabinoids with plant derived products. Can you give a layman's overview of the difference and significance from a regulatory standpoint?
The Cannabis plant is known to have more than 100 different cannabinoid molecules. These molecules can possess diverse activity at the cellular level in multiple organs in the body. Plant-derived molecules are very hydrophobic or not that soluble in water. The lack of significant water solubility makes these molecules difficult to administer into the body, especially by oral ingestion. Nemus' cannabinoid molecules have been re-engineered to make them chemically more hydrophilic or water soluble, so they can traverse cellular membranes easier with the goal that they can be absorbed in a more predictable and safer way. Patents have been issued for compounds licensed by Nemus that have intellectual property claims related to composition of matter, methods of synthesis, and methods of use.
Nemus cannabinoid molecules are being chemically synthesized to meet purity and scale-up criteria for eventual commercialization. The synthetic manufacturing process must meet DEA and FDA specifications for cannabinoid-based drug product. Furthermore, Nemus plans to conduct the necessary pre-clinical and clinical studies so these molecules meet the specifications to be an approvable drug product.
Q. In terms of competition in the space with GW Pharma, Zynerba, and Insys, how do you feel NEMUS should be compared?
Nemus is an early-stage developmental company compared to the listed cannabinoid-market incumbents. We aspire to be a second-generation market disruptor.
a) Nemus does not rely on plant extraction for its drug product candidates and in fact, by virtue of biosynthetic manufacturing, can potentially develop high-purity active pharmaceutical ingredients (APIs) with associated shorter manufacturing times.
b) Nemus's portfolio consists of re-engineered cannabinoids, a prodrug of THC and an analogue of CBD. These drug product candidates are designed to have multiple routes of administration specific to the disease indication that could potentially give Nemus a competitive advantage on issues of bio-distribution, bioavailability, and pharmacokinetics.
c) Unlike companies that use traditional plant cannabinoids, Nemus' licensed bio-engineered molecules have been issued patents for composition of matter as well as methods of use. Consequently, Nemus may not have to rely on orphan indications for market exclusivity but could approach entire therapeutic areas globally. These markets, namely glaucoma, pain, methicillin-resistant Staphylococcus aureus (MRSA) and CINV, are all multi-billion dollar global opportunities with an urgent medical need for newer, safe and effective therapies.
d) Nemus currently holds some market distinctions, including, to our knowledge, being the only cannabinoid company developing a portfolio of drug candidates for use in ophthalmology, with a leading indication being glaucoma; the only cannabinoid company developing an anti-infective platform against multiple infectious agents; the only cannabinoid company utilizing biosynthetic manufacturing; and the only cannabinoid company with prodrug and analogue capability with multiple potential routes of administration including ocular, trans-mucosal/buccal, transdermal, and transmembranous delivery that avoids first-pass metabolism by the liver.
Q. With GW Pharma being the most advanced in the clinic with a market cap of almost $3 Billion, how do you see NEMUS moving forward with GW having the first mover advantage?
With a pipeline bio-engineered with the goal of better target-organ access, we believe Nemus can be a classical second-mover to capitalize on unmet medical needs of first-in-class drugs. Those needs include: more rapid onset of action, predictable bioavailability and pharmacokinetics, routes of administration that avoid first-pass liver metabolism, versatility in dosing mechanisms, and efficient API manufacturing. We believe Nemus will be able to enter large therapeutic areas versus having to focus on orphan indications.
Q. From a regulatory standpoint at the federal level and some of the laws that have been passed, do you believe the current administration will loosen plant-based cannabinoids versus pharmaceutical, and how would that impact your business model?
Time will tell what the new administration's position will be. For pharmaceutical developers, the pathway to drug approval is carefully delineated and all drugs must meet the criteria set by the regulatory agencies. If marijuana is re-scheduled as a Schedule II drug, pharmaceutical developers will be required to conduct clinical trials and have scientifically rigorous data to make claims about and promote the medicinal benefits of the Cannibas plant as was done with other Schedule II medications like oxycontin. Nemus plans to conduct research and development in accordance with FDA standards so the proper regulatory filings can be made to reach drug approval.
Q. Looking forward at how you advance your portfolio, should investors be looking at structures such as co-development or licensing agreements, and are there examples of such in the cannabinoid industry?
It will come as no surprise to anyone that drug development is time consuming and expensive, especially on a global scale. Nemus has access to patents and compounds that have shown activity in both in vitro and animal testing. To maximize shareholder value, Nemus is open to explore strategic collaborations with partners that can help expedite our goals to commercialize our pipeline. That collaboration could possibly take the form of a co-development deal, an in-licensing of our products, or an outright acquisition of a promising platform, especially one that requires resources that an early-stage biotechnology company may not have.
Mature companies in the cannabinoid sector like GW Pharma have also partnered with larger firms, especially those that can provide development capital and provide sales capabilities in overseas territories. We anticipate that this will be more the rule than the exception as breakthrough companies in the pharmaceuticalized cannabinoid space expand their capabilities.
Q. In closing, given all of the developments that have occurred both in NEMUS and the cannabinoid sector over the past year, what should investors focus on in 2017?
I believe investors will see strides in the cannabinoid sector beyond pain and epilepsy as companies like Nemus advance other cannabinoid molecules for newer indications. I feel the cannabinoid sector is a hyper-competitive space and there will be greater emphasis to expand treatment options utilizing different routes of administration to enhance safety and the clinical response. Nemus has licenses from the University of Mississippi that allow the company to develop unique methods to administer our novel forms of cannabinoids and we look forward to introducing these approaches into the development pipeline in 2017.
End interview
While technically not a marijuana stock, NMUS will most likely rise and fall with the sector, at least until the market fully understands the differentiating features of the company. NMUS is certainly a stock to keep an eye on in the near term, as cannabinoids are becoming increasingly popular in clinical trials and are demonstrating significant therapeutic benefit for a host of disease and illness.
Thanks to Brian Murphy and the rest of the management team at NMUS for taking the time to update shareholders. While all small caps have risk, the ones that have a clear plan of action hold the most promise of making it out of penny land alive. For NMUS, as long as management can stay focused to their tasks at hand and remain steadfast to their corporate responsibilities, they may fare well in the next 12-24 months.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
http://seekingalpha.com/article/4041487-sit-nemus-bioscience-cannabinoids-focus
(CLINICAL TRIALS) In My Opinion, Buy as much as you can and HOLD IT LONG TERM!
They will be announcing Clinical Trial Progress during the current quarter and beyond.
Nemus Bioscience Announces Milestones in the Development of Fully Synthetic Clinical-Grade Active Pharmaceutical Ingredient (API) for Drug Candidates NB1111 and NB2111 and Formulation Contract with AMRI and Catalent Pharma Solutions
COSTA MESA, CA / ACCESSWIRE / December 1, 2016 / NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that work performed in conjunction with its API contract developer and manufacturer, Albany Molecular Research Inc. (NASDAQ: AMRI), resulted in a synthetic pathway to manufacture the clinical-grade proprietary prodrug tetrahydrocannabinol-valine-hemisuccinate (THCVHS), including the ability to scale-up production. In addition, the purity of the API achieved a standard exceeding FDA requirements of being at least 99.5% pure. Nemus has subsequently contracted with Catalent Pharma Solutions (Catalent) to begin formulation work associated with NB2111, the candidate product for managing chemotherapy-induced nausea and vomiting (CINV).
"Reliable and consistent API manufacturing is a major step necessary for human testing, regulatory approval and ultimate commercialization of a candidate molecule. The Nemus cannabinoid compounds of NB1111, which is intended for the treatment of glaucoma and NB2111, which is intended for managing chemotherapy-induced nausea and vomiting (CINV) both utilize the patented prodrug of THC as the active ingredient," commented Brian Murphy, M.D., M.B.A., CEO and Chief Medical Officer of Nemus. "In preparing for a pre-IND meeting with the FDA, the company is focused on formulation development of NB1111 and NB2111 to meet chemistry-manufacturing-controls (CMC) requirements of the FDA. We are working with Catalent in the formulation process to achieve a clinical-grade delivery of NB2111 in CINV."
"The company is exploring formulation options for the delivery of NB1111 into the eye. Nemus anticipates this process to be completed in the first quarter of 2017 resulting in a collaboration with an ocular drug delivery formulator that will help bring the candidate- glaucoma therapy forward to satisfy regulatory requirements for human testing," stated Dr. Murphy.
FORWARD LOOKING STATEMENTS
https://www.otcmarkets.com/stock/NMUS/news
$NMUS OWNS TONS OF CANNABINOID PATENTS/IP, WORTH A FORTUNE!
Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Receives Intellectual Property Protection in the European Union (E.U.) and Australia Following Patents issued in the United States and Japan
COSTA MESA, CA / ACCESSWIRE / December 12, 2016 / NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that a patent has been granted covering the company's proprietary prodrug of THC, THC-valine-hemisuccinate (THCVHS), in Australia, and that another patent will be allowed covering THCVHS in the E.U., pending company identification of E.U. member countries for formal patent issuance. These patents, which are licensed to the Company by the University of Mississippi, complement patents granted in the United States on THCVHS in 2014 and Japan in 2015, which are also licensed to the Company by the University of Mississippi. THCVHS is the active pharmaceutical ingredient (API) in Nemus' drug candidates known as NB1111, which is being developed for the management and treatment of glaucoma, and NB1222, which is being developed for the management of chemotherapy-induced nausea and vomiting.
"The core API of the lead Nemus developmental candidates, NB1111 and NB1222, now has intellectual property protection in major markets worldwide. This is an important development for Nemus, which is focused on developing cannabinoid therapeutics. Having patents granted in multiple territories, especially in the U.S., Japan, and the E.U., which are the top three commercial markets for pharmaceutical products in the world, strengthens the company's ability to explore potential collaborations with pharmaceutical and biotech companies," commented Brian Murphy, M.D., CEO and Chief Medical Officer of Nemus.
"The value of cannabinoids formulated for therapeutic uses is being recognized on a global scale. We are happy that our proprietary technology is being appreciated for its uniqueness and look forward to helping advance this science to the commercial stage," stated Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research at the University of Mississippi and principal investigator on the projects.
"Nemus and the University are also working on unique molecular approaches to other cannabinoid derivatives in an effort to create therapeutic candidates that can be customized for specific medical conditions. We view this as an integral part of our goal to be a leader in the development of second- and third-generation cannabinoid medications," said Dr. Murphy.
https://www.otcmarkets.com/stock/NMUS/news/Nemus-Bioscience-Reports-Prodrug-of-Tetrahydrocannabinol--THC--Receives-Intellectual-Property-Protection-in-the-European-Union--E-U---and-Australia-Following-Patents-issued-in-the-U-S--and-Japan?id=146822&b=y
https://www.otcmarkets.com/stock/NMUS/news
$NMUS PARTNERED WITH NASDAQ $AMRI, Signs Agreement With Albany Molecular Research Inc.
NEMUS Bioscience, Inc. Signs Agreement With Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredients
COSTA MESA, CA and ALBANY, NY--(Marketwired - Feb 8, 2016) - NEMUS Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs, today announced an agreement with Albany Molecular Research Inc. (NASDAQ: AMRI) for the development and manufacture of NEMUS' proprietary cannabinoid-based active pharmaceutical ingredients. The agreement will capitalize on AMRI's process chemistry expertise in the synthesis and formulation of NEMUS' proprietary prodrug of tetrahydrocannabinol (THC). This molecule forms the basis of NB1111, NEMUS' compound in development for the treatment of glaucoma, and NB1222, for the management of chemotherapy-induced nausea and vomiting (CINV).
"Advancing our lead therapeutic candidates into the manufacturing stage is a major milestone for our company," commented Brian Murphy, M.D., CEO-CMO of NEMUS. "This permits us to move from testing prototypic formulations to having the ability to accumulate API-based data in pre-clinical and clinical studies, which is pivotal for submission to regulatory agencies."
"AMRI looks forward to working with NEMUS to bring this new class of cannabinoid-based therapies through the developmental process," said Christopher Conway, Senior Vice President of Discovery and Development Services at AMRI. "AMRI will focus on manufacturing synthetic versions of NEMUS' proprietary prodrug of THC at our U.S. Drug Enforcement Administration (DEA) approved facilities."
Dr. Murphy concluded: "Eye disease and the oncologic-related palliative care markets are in need of new classes of compounds to benefit patients. There is a significant need for better treatments for patients suffering from a variety of diseases including adverse events related to their cancer care. We are excited to collaborate with a highly-experienced manufacturer like AMRI, to bring new medications such as cannabinoid-based therapeutics, to these areas of significant unmet medical need."
HERE'S_THE_KEY_TO_WHY_$NMUS_IS_HEADED_WAY_UP!!!$1+__SOON_IN_MY_OPINION!!!
WE HAVE EXCLUSIVE ACCESS TO 49 YEARS WORTH OF CANNABIS FEDERAL RESEARCH ! NOT EVEN OUR COMPETITORS $GWPH, $ZYNE, $INSY, OR $CARA 's HAVE THIS TYPE OF RESEARCH AT THEIR DISPOSAL! BTW $ETST RECENTLY EXPLODED IN THE PAST COUPLE OF DAYS. THEY ARE A DIRECT COMPETITOR AND HAVE A MARKET CAP AT ALMOST 7X $NMUS AND THEY DONT EVEN HAVE THIS TYPE OF INTELLECTUAL PROPERTY!
WE OWN THE EXCLUSIVE RIGHTS!!
PER THE RECENT CEO INTERVIEW:
NMUS is growing and is charting a course for growth in the near term. From managements perspective, they are already well on their way.
Q. In looking at NEMUS' portfolio of cannabinoid product candidates and the unique relationship with The University of Mississippi, can you provide us with an overview of the pipeline and patent portfolio?
The University of Mississippi has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968. By virtue of the University's 49-year experience with the Cannabis plant, Nemus benefits tremendously from the University's knowledge. Nemus is the sole developmental and commercialization partner with the University and has exclusive, global licenses to intellectual property related to these molecules.
HERE'S_THE_KEY_TO_WHY_$NMUS_IS_HEADED_WAY_UP!!!$1+__SOON_IN_MY_OPINION!!!
WE HAVE EXCLUSIVE ACCESS TO 49 YEARS WORTH OF CANNABIS FEDERAL RESEARCH ! NOT EVEN OUR COMPETITORS $GWPH, $ZYNE, $INSY, OR $CARA 's HAVE THIS TYPE OF RESEARCH AT THEIR DISPOSAL! BTW $ETST RECENTLY EXPLODED IN THE PAST COUPLE OF DAYS. THEY ARE A DIRECT COMPETITOR AND HAVE A MARKET CAP AT ALMOST 7X $NMUS AND THEY DONT EVEN HAVE THIS TYPE OF INTELLECTUAL PROPERTY!
WE OWN THE EXCLUSIVE RIGHTS!!
PER THE RECENT CEO INTERVIEW:
NMUS is growing and is charting a course for growth in the near term. From managements perspective, they are already well on their way.
Q. In looking at NEMUS' portfolio of cannabinoid product candidates and the unique relationship with The University of Mississippi, can you provide us with an overview of the pipeline and patent portfolio?
The University of Mississippi has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968. By virtue of the University's 49-year experience with the Cannabis plant, Nemus benefits tremendously from the University's knowledge. Nemus is the sole developmental and commercialization partner with the University and has exclusive, global licenses to intellectual property related to these molecules.
$NMUS FULL CEO Interview A Sit Down With Nemus Bioscience; Cannabinoids In Focus - Nemus Bioscience, Inc. (OTCMKTS:NMUS) | Seeking Alpha
A Sit Down With Nemus Bioscience; Cannabinoids In Focus
Feb. 1, 2017 11:06 AM ET Nemus Bioscience, Inc. (NMUS)
Summary
Cannabinoids are fast becoming an interesting market with proven efficacy for a host of disease and illness.
Separating cannabinoid companies from marijuana stocks is a critically important aspect of investing in the sector.
NMUS is well connected with educational institutions, has some strong license agreements and may capitalize from increased interest in cannabinoid based therapy.
I have received enough questions from followers about Nemus Bioscience (OTCQB:NMUS) that my curiosity was finally piqued to the point of action. While Seeking Alpha has certainly presented a fair share of information and analysis about NMUS, the time is probably ripe for management to provide a detailed update as to the current state of NMUS, as well as to provide guidance on its near term ambitions.
Being that as it may, I went straight to the source, and NMUS management was more than receptive to providing some current data and to provide investors with a fresh take on what NMUS is working to accomplish.
From my point of view, NMUS is growing and is charting a course for growth in the near term. From managements perspective, they are already well on their way.
Q. In looking at NEMUS' portfolio of cannabinoid product candidates and the unique relationship with The University of Mississippi, can you provide us with an overview of the pipeline and patent portfolio?
The University of Mississippi has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968. By virtue of the University's 49-year experience with the Cannabis plant, Nemus benefits tremendously from the University's knowledge. Nemus is the sole developmental and commercialization partner with the University and has exclusive, global licenses to intellectual property related to these molecules.
Those licenses include access to intellectual property for both a prodrug of tetrahydrocannabinol (THC) and an analogue of cannabidiol (CBD). The THC-prodrug is being developed as a therapeutic agent for glaucoma and chemotherapy-induced nausea and vomiting (CINV). The analogue of CBD is being explored as a possible therapeutic for chemotherapy-induced peripheral neuropathy (CIPN) and other pain syndromes. Lastly, Nemus is developing cannabinoid-based platforms for use as anti-infectives, especially for use against bacteria and viruses that have developed resistance to established therapies.
Q. Often times investors confuse pharmaceutical-based cannabinoids with plant derived products. Can you give a layman's overview of the difference and significance from a regulatory standpoint?
The Cannabis plant is known to have more than 100 different cannabinoid molecules. These molecules can possess diverse activity at the cellular level in multiple organs in the body. Plant-derived molecules are very hydrophobic or not that soluble in water. The lack of significant water solubility makes these molecules difficult to administer into the body, especially by oral ingestion. Nemus' cannabinoid molecules have been re-engineered to make them chemically more hydrophilic or water soluble, so they can traverse cellular membranes easier with the goal that they can be absorbed in a more predictable and safer way. Patents have been issued for compounds licensed by Nemus that have intellectual property claims related to composition of matter, methods of synthesis, and methods of use.
Nemus cannabinoid molecules are being chemically synthesized to meet purity and scale-up criteria for eventual commercialization. The synthetic manufacturing process must meet DEA and FDA specifications for cannabinoid-based drug product. Furthermore, Nemus plans to conduct the necessary pre-clinical and clinical studies so these molecules meet the specifications to be an approvable drug product.
Q. In terms of competition in the space with GW Pharma, Zynerba, and Insys, how do you feel NEMUS should be compared?
Nemus is an early-stage developmental company compared to the listed cannabinoid-market incumbents. We aspire to be a second-generation market disruptor.
a) Nemus does not rely on plant extraction for its drug product candidates and in fact, by virtue of biosynthetic manufacturing, can potentially develop high-purity active pharmaceutical ingredients (APIs) with associated shorter manufacturing times.
b) Nemus's portfolio consists of re-engineered cannabinoids, a prodrug of THC and an analogue of CBD. These drug product candidates are designed to have multiple routes of administration specific to the disease indication that could potentially give Nemus a competitive advantage on issues of bio-distribution, bioavailability, and pharmacokinetics.
c) Unlike companies that use traditional plant cannabinoids, Nemus' licensed bio-engineered molecules have been issued patents for composition of matter as well as methods of use. Consequently, Nemus may not have to rely on orphan indications for market exclusivity but could approach entire therapeutic areas globally. These markets, namely glaucoma, pain, methicillin-resistant Staphylococcus aureus (MRSA) and CINV, are all multi-billion dollar global opportunities with an urgent medical need for newer, safe and effective therapies.
d) Nemus currently holds some market distinctions, including, to our knowledge, being the only cannabinoid company developing a portfolio of drug candidates for use in ophthalmology, with a leading indication being glaucoma; the only cannabinoid company developing an anti-infective platform against multiple infectious agents; the only cannabinoid company utilizing biosynthetic manufacturing; and the only cannabinoid company with prodrug and analogue capability with multiple potential routes of administration including ocular, trans-mucosal/buccal, transdermal, and transmembranous delivery that avoids first-pass metabolism by the liver.
Q. With GW Pharma being the most advanced in the clinic with a market cap of almost $3 Billion, how do you see NEMUS moving forward with GW having the first mover advantage?
With a pipeline bio-engineered with the goal of better target-organ access, we believe Nemus can be a classical second-mover to capitalize on unmet medical needs of first-in-class drugs. Those needs include: more rapid onset of action, predictable bioavailability and pharmacokinetics, routes of administration that avoid first-pass liver metabolism, versatility in dosing mechanisms, and efficient API manufacturing. We believe Nemus will be able to enter large therapeutic areas versus having to focus on orphan indications.
Q. From a regulatory standpoint at the federal level and some of the laws that have been passed, do you believe the current administration will loosen plant-based cannabinoids versus pharmaceutical, and how would that impact your business model?
Time will tell what the new administration's position will be. For pharmaceutical developers, the pathway to drug approval is carefully delineated and all drugs must meet the criteria set by the regulatory agencies. If marijuana is re-scheduled as a Schedule II drug, pharmaceutical developers will be required to conduct clinical trials and have scientifically rigorous data to make claims about and promote the medicinal benefits of the Cannibas plant as was done with other Schedule II medications like oxycontin. Nemus plans to conduct research and development in accordance with FDA standards so the proper regulatory filings can be made to reach drug approval.
Q. Looking forward at how you advance your portfolio, should investors be looking at structures such as co-development or licensing agreements, and are there examples of such in the cannabinoid industry?
It will come as no surprise to anyone that drug development is time consuming and expensive, especially on a global scale. Nemus has access to patents and compounds that have shown activity in both in vitro and animal testing. To maximize shareholder value, Nemus is open to explore strategic collaborations with partners that can help expedite our goals to commercialize our pipeline. That collaboration could possibly take the form of a co-development deal, an in-licensing of our products, or an outright acquisition of a promising platform, especially one that requires resources that an early-stage biotechnology company may not have.
Mature companies in the cannabinoid sector like GW Pharma have also partnered with larger firms, especially those that can provide development capital and provide sales capabilities in overseas territories. We anticipate that this will be more the rule than the exception as breakthrough companies in the pharmaceuticalized cannabinoid space expand their capabilities.
Q. In closing, given all of the developments that have occurred both in NEMUS and the cannabinoid sector over the past year, what should investors focus on in 2017?
I believe investors will see strides in the cannabinoid sector beyond pain and epilepsy as companies like Nemus advance other cannabinoid molecules for newer indications. I feel the cannabinoid sector is a hyper-competitive space and there will be greater emphasis to expand treatment options utilizing different routes of administration to enhance safety and the clinical response. Nemus has licenses from the University of Mississippi that allow the company to develop unique methods to administer our novel forms of cannabinoids and we look forward to introducing these approaches into the development pipeline in 2017.
End interview
While technically not a marijuana stock, NMUS will most likely rise and fall with the sector, at least until the market fully understands the differentiating features of the company. NMUS is certainly a stock to keep an eye on in the near term, as cannabinoids are becoming increasingly popular in clinical trials and are demonstrating significant therapeutic benefit for a host of disease and illness.
Thanks to Brian Murphy and the rest of the management team at NMUS for taking the time to update shareholders. While all small caps have risk, the ones that have a clear plan of action hold the most promise of making it out of penny land alive. For NMUS, as long as management can stay focused to their tasks at hand and remain steadfast to their corporate responsibilities, they may fare well in the next 12-24 months.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
http://seekingalpha.com/article/4041487-sit-nemus-bioscience-cannabinoids-focus
NMUS Stock Price & News - Nemus Bioscience Inc. - Wall Street Journal
http://quotes.wsj.com/NMUS
FLOAT_REMAINS_UNCHANGED_AT_5,005,713
Market Value1 $9,401,590 a/o Feb 02, 2017
Authorized Shares 236,000,000 a/o Feb 01, 2017
Outstanding Shares 22,438,163 a/o Feb 01, 2017
-Restricted 13,494,621 a/o Feb 01, 2017
-Unrestricted 8,943,542 a/o Feb 01, 2017
Held at DTC Not Available
Float 5,005,713 a/o Mar 23, 2016
Par Value
http://www.otcmarkets.com/stock/NMUS/profile
FLOAT_REMAINS_UNCHANGED_AT_5,005,713
Market Value1 $9,401,590 a/o Feb 02, 2017
Authorized Shares 236,000,000 a/o Feb 01, 2017
Outstanding Shares 22,438,163 a/o Feb 01, 2017
-Restricted 13,494,621 a/o Feb 01, 2017
-Unrestricted 8,943,542 a/o Feb 01, 2017
Held at DTC Not Available
Float 5,005,713 a/o Mar 23, 2016
Par Value
http://www.otcmarkets.com/stock/NMUS/profile
$NMUS_____$ETST Running up!
$NMUS_____$ETST Running up!
$NMUS and $ETST Breaking Out!
$NMUS and $ETST Breaking Out!
Huge News $GRNH Greengro Technologies, Inc. Unveils New 22,000 Sq. Ft. Fully Automated
Vertical Hydrogarden Commercial PV Solar Glasshouse
Tailored State-of-the-Art Hydroponic Vertical Commercial Cannabis Growing Facility Response to AB 243
ANAHEIM, Calif., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Greengro Technologies, Inc. (OTC PINK:GRNH) a world-class provider of eco-friendly green technologies, announced today that as the demand for industrial cutting-edge growing solutions continues to strengthen, Greengro steps forward with a PV solar glass greenhouse precisely designed to facilitate the industrial cannabis grower’s cultivation and harvesting requirements.
Greengro subsidiary Vertical HydroGarden, Inc. is a premier retailer of year-round hydroponic supplies. Vertical HydroGarden is the industry leader in modular, automated hydroponic grow rooms, portable grow-containers, glass greenhouses, hydroponic and aquaponics supplies and cultivation consulting services.
Pullback already occurred. Will Continue Running!
This will be Another $AXIM $ETST! Watch and Learn!!
Load Up while you can, Same Story as ETST! Way overlooked. This will be over $1 before you can blink!
Sub 5 Million Share Float! All other shares are RESTRICTED!!!!
$NMUS Nemus has exclusive partnership w The University of Mississippi & federally permitted & licensed to cultivate cannabis for R&D #NMUS
Loading ETST and NMUS, both comparable to AXIM
NMUS_Can_Run_Like__ET$T__Similiar_plays!
Potstocks_To_Watch__$ETST___and___$NMUS___
Marijuana__Plays__$ETST___and___$NMUS___On____A____Run!
$ETST___and___$NMUS___On____A____Run!
$ETST___and___$NMUS___On____Steroids!